Cyclin-dependent kinase 4/6 inhibition in cancer therapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.Journal of the National Cancer Institute · 2017
   Trial
2. Heat shock proteins and cancer: The FoxM1 connection.Biochemical pharmacology · 2023
   Review
3. C-demethylation and 1, 2-amino shift in (E)-2-(1-(3-aminophenyl) ethylidene)hydrazinecarboxamide to (E)-2-(2-aminobenzylidene)hydrazinecarboxamide and their applications.Scientific reports · 2020
   Article
4. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.International journal of molecular sciences · 2020
   Review
5. Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.Scientific reports · 2019
   Article
6. Cdk6 contributes to cytoskeletal stability in erythroid cells.Haematologica · 2017
   Article
7. Identification of RECQ1-regulated transcriptome uncovers a role of RECQ1 in regulation of cancer cell migration and invasion.Cell cycle (Georgetown, Tex.) · 2014
   Article
8. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer.Breast cancer (Dove Medical Press) · 2014
   Review
9. miR-124 radiosensitizes human glioma cells by targeting CDK4.Journal of neuro-oncology · 2013
   Article
10. K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway.Cell cycle (Georgetown, Tex.) · 2013
    Article

Corrections and comments

• Comment on
  CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.2012
• Comment on
  Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.2012

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as